NO954293D0 - Steroider med en 17-spirometylenlakton eller -laktolgruppe - Google Patents

Steroider med en 17-spirometylenlakton eller -laktolgruppe

Info

Publication number
NO954293D0
NO954293D0 NO954293A NO954293A NO954293D0 NO 954293 D0 NO954293 D0 NO 954293D0 NO 954293 A NO954293 A NO 954293A NO 954293 A NO954293 A NO 954293A NO 954293 D0 NO954293 D0 NO 954293D0
Authority
NO
Norway
Prior art keywords
halogen
alkyl
optionally substituted
group
steroids
Prior art date
Application number
NO954293A
Other languages
English (en)
Other versions
NO954293L (no
NO305252B1 (no
Inventor
Johannes Antonius Mar Hamersma
Jaap Van Der Louw
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of NO954293D0 publication Critical patent/NO954293D0/no
Publication of NO954293L publication Critical patent/NO954293L/no
Publication of NO305252B1 publication Critical patent/NO305252B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J19/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 by a lactone ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0092—Alkenyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/001—Lactones
    • C07J21/003—Lactones at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO954293A 1994-10-27 1995-10-26 Steroid, farmas°ytisk preparat inneholdende dette og anvendelse av steroidet NO305252B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94203117 1994-10-27

Publications (3)

Publication Number Publication Date
NO954293D0 true NO954293D0 (no) 1995-10-26
NO954293L NO954293L (no) 1996-04-29
NO305252B1 NO305252B1 (no) 1999-04-26

Family

ID=8217314

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954293A NO305252B1 (no) 1994-10-27 1995-10-26 Steroid, farmas°ytisk preparat inneholdende dette og anvendelse av steroidet

Country Status (26)

Country Link
US (1) US5741786A (no)
EP (1) EP0709394B1 (no)
JP (1) JPH08225590A (no)
KR (1) KR100402636B1 (no)
CN (1) CN1052237C (no)
AT (1) ATE199015T1 (no)
AU (1) AU689642B2 (no)
BR (1) BR9504576A (no)
CA (1) CA2161490A1 (no)
CZ (1) CZ287346B6 (no)
DE (1) DE69520022T2 (no)
DK (1) DK0709394T3 (no)
ES (1) ES2157290T3 (no)
FI (1) FI113542B (no)
GR (1) GR3035713T3 (no)
HU (1) HU221192B1 (no)
IL (1) IL115659A (no)
NO (1) NO305252B1 (no)
NZ (1) NZ280325A (no)
PL (1) PL187083B1 (no)
PT (1) PT709394E (no)
RU (1) RU2168516C2 (no)
SG (1) SG33569A1 (no)
TR (1) TR199501327A2 (no)
TW (1) TW339337B (no)
ZA (1) ZA958963B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
ATE473759T1 (de) 1998-05-22 2010-07-15 Univ Leland Stanford Junior Bifunktionelle moleküle sowie darauf basierende therapien.
US6043235A (en) * 1999-07-21 2000-03-28 Research Triangle Institute 11β-aryl-17, 17-spirothiolane-substituted steroids
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
CN103259027A (zh) 2005-04-28 2013-08-21 普罗透斯数字保健公司 药物信息系统
JP2009508494A (ja) 2005-09-16 2009-03-05 ラプトール ファーマシューティカル インコーポレイテッド Ｃｒを含むタンパク質に対して特異的な受容体−結合タンパク質（ｒａｐ）変異体を含む組成物およびその使用
PT2398500T (pt) 2009-02-20 2019-06-14 2 Bbb Medicines B V Sistema de entrega de medicamentos à base de glutationas
TWI556839B (zh) 2009-05-06 2016-11-11 研究室護膚股份有限公司 包含活性劑－磷酸鈣粒子複合物之皮膚遞送組成物及其使用方法
CA3174401A1 (en) * 2020-04-03 2021-10-07 Daan De Kubber Method of draining water

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2875199A (en) * 1958-04-22 1959-02-24 Searle & Co Lactones of 17-carboxyalkylated estra-1, 3, 5(10)-triene-3, 17-diols and 3-ethers
US3547912A (en) * 1968-07-29 1970-12-15 American Home Prod Derivatives of 2h-pyran-3(6h)-ones and preparation thereof
US3764596A (en) * 1971-06-22 1973-10-09 Sandoz Ag 17-dihydrofuranyl-substituted steroids
ES2053714T3 (es) * 1987-12-12 1994-08-01 Akzo Nv Proceso para la preparacion de 11-arilesteroides.
FR2688004A1 (fr) * 1992-02-27 1993-09-03 Roussel Uclaf Nouveaux sterouides comportant en position 17 un radical methylene lactone, leur procede et des intermediaires de preparation, leur application comme medicaments.

Also Published As

Publication number Publication date
DE69520022D1 (de) 2001-03-08
KR960014152A (ko) 1996-05-22
AU689642B2 (en) 1998-04-02
KR100402636B1 (ko) 2004-02-05
TR199501327A2 (tr) 1996-06-21
SG33569A1 (en) 1996-10-18
GR3035713T3 (en) 2001-07-31
JPH08225590A (ja) 1996-09-03
BR9504576A (pt) 1997-05-20
ZA958963B (en) 1996-05-23
RU2168516C2 (ru) 2001-06-10
IL115659A (en) 2000-06-01
ES2157290T3 (es) 2001-08-16
CN1131158A (zh) 1996-09-18
FI113542B (fi) 2004-05-14
IL115659A0 (en) 1996-01-19
PL187083B1 (pl) 2004-05-31
AU3445795A (en) 1996-05-09
US5741786A (en) 1998-04-21
HU9503068D0 (en) 1995-12-28
DK0709394T3 (da) 2001-06-18
HU221192B1 (en) 2002-08-28
CN1052237C (zh) 2000-05-10
TW339337B (en) 1998-09-01
EP0709394A3 (en) 1996-09-18
EP0709394A2 (en) 1996-05-01
FI955108A (fi) 1996-04-28
FI955108A0 (fi) 1995-10-26
TR199501327A3 (no) 1996-06-21
NO954293L (no) 1996-04-29
DE69520022T2 (de) 2001-06-13
CA2161490A1 (en) 1996-04-28
NZ280325A (en) 1997-03-24
NO305252B1 (no) 1999-04-26
PL311135A1 (en) 1996-04-29
ATE199015T1 (de) 2001-02-15
CZ287346B6 (en) 2000-10-11
EP0709394B1 (en) 2001-01-31
HUT73482A (en) 1996-08-28
PT709394E (pt) 2001-06-29
CZ275595A3 (en) 1996-05-15

Similar Documents

Publication Publication Date Title
DK0709394T3 (da) Steroider med en 17-spiromethylen-lacton- eller -lactol-gruppe
ES486991A1 (es) Un procedimiento para la preparacion de un derivado de car- boestirilo
ES417012A2 (es) Mejoras introducidas en el objeto de la patente principal, num. 399.057.
MX9207394A (es) Esteroides de 17-espirofuran-3'-ilideno.
PT955286E (pt) Derivados do di-hidro ou tetra-hidronaftaleno tendo uma actividade (ani-)estrogenica
IL117497A (en) 17-difluoromethylene estratriene derivatives and pharmaceutical compositions containing the same
DE69305659D1 (de) 17-Phenyl-substituierte Steroide mit cardiotonischer Wirksamkeit

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees